Literature DB >> 23392796

Radiologic-histological correlation of hepatocellular carcinoma treated via pre-liver transplant locoregional therapies.

Galal El-Gazzaz1, Achuthan Sourianarayanane, K V Narayanan Menon, Juan Sanabria, Koji Hashimoto, Cristiano Quintini, Dympna Kelly, Bijan Eghtesad, Charles Miller, John Fung, Federico Aucejo.   

Abstract

BACKGROUND: Locoregional therapies (LRTs) are treatments to achieve local control of hepatocellular carcinoma (HCC). Correlation between radiologic response to LRT and degree of induced tumor necrosis is not well understood. The aim of this study was to evaluate different levels of radiologic response after pre-liver transplant (LT) LRT and its correlation with percentage of tumor necrosis on explanted histopathology.
METHODS: Institutional Review Board approved LT database was queried for treated HCC in patients undergoing LT. Radiologic response was evaluated to predict tumor necrosis in the explanted liver. Tumor response was evaluated 1 to 3 months after LRT with computed tomography or MRI via Response Evaluation Criteria in Solid Tumors (RECIST), and European Association for the Study of the Liver (EASL) guidelines. LRT was repeated as needed until time of LT. Histological tumor necrosis was graded as complete (100%), partial (50%-99%), or poor (<50%).
RESULTS: Between 2002 and 2011, 128 patients (97 men and 31 women) received pre-LT LRT including transarterial therapy (93), radiofrequency ablation (20), or combination of both (15). The mean age of the patients was 58+/-9 years. Their mean follow-up was 35+/-27 months. The median waitlist time was 55 days. One hundred (78%) patients had HCC within the Milan criteria at the initial radiologic diagnosis. Nineteen (15%) of the patients had complete tumor necrosis on histopathology analysis. Fifty (39%) of the patients exhibited partial necrosis, 52 (41%) showed poor or no necrosis and 7 (5%) showed progressive disease. The overall pre-LT radiologic staging was correlated with explant pathology in 73 (57%) of the patients. Underestimated tumor stage was noted in 49 (38%) patients, and overestimated tumor stage in 6 (5%) patients. The post-LT 3-year overall survival and disease free survival were 82% and 80%, and the rates for complete and partial tumor necrosis were 100% vs 78% (P=0.02) and 100% vs 75% (P=0.03), respectively.
CONCLUSIONS: In the current era, interpretation of radiologic response after LRT for HCC does not correlate accurately with histologic tumor necrosis. Total tumor necrosis is the goal of LRT; therefore, evolution in its performance is needed. Similarly, ways to predict therapy induced tumor necrosis via radiological investigation need to be improved.

Entities:  

Mesh:

Year:  2013        PMID: 23392796     DOI: 10.1016/s1499-3872(13)60003-x

Source DB:  PubMed          Journal:  Hepatobiliary Pancreat Dis Int


  9 in total

1.  3D versus 2D contrast-enhanced sonography in the evaluation of therapeutic response of hepatocellular carcinoma after locoregional therapies: preliminary findings.

Authors:  Tommaso Vincenzo Bartolotta; Adele Taibbi; Domenica Matranga; Massimo Midiri; Roberto Lagalla
Journal:  Radiol Med       Date:  2015-02-20       Impact factor: 3.469

2.  Ischemia Induces Quiescence and Autophagy Dependence in Hepatocellular Carcinoma.

Authors:  Terence P F Gade; Elizabeth Tucker; Michael S Nakazawa; Stephen J Hunt; Waihay Wong; Bryan Krock; Charles N Weber; Gregory J Nadolski; Timothy W I Clark; Michael C Soulen; Emma E Furth; Jeffrey D Winkler; Ravi K Amaravadi; M Celeste Simon
Journal:  Radiology       Date:  2017-03-02       Impact factor: 11.105

3.  Antitumor Activity of Chitosan-Coated Iron Oxide Nanocomposite Against Hepatocellular Carcinoma in Animal Models.

Authors:  Monda M M Badawy; Gehan R Abdel-Hamid; Hebatallah E Mohamed
Journal:  Biol Trace Elem Res       Date:  2022-07-22       Impact factor: 4.081

4.  Validation of the Liver Imaging Reporting and Data System Treatment Response Criteria After Thermal Ablation for Hepatocellular Carcinoma.

Authors:  Katherine S Cools; Andrew M Moon; Lauren M B Burke; Katrina A McGinty; Paula D Strassle; David A Gerber
Journal:  Liver Transpl       Date:  2019-12-20       Impact factor: 5.799

5.  Comparison of hepatic MDCT, MRI, and DSA to explant pathology for the detection and treatment planning of hepatocellular carcinoma.

Authors:  Lauren M Ladd; Temel Tirkes; Mark Tann; David M Agarwal; Matthew S Johnson; Bilal Tahir; Kumaresan Sandrasegaran
Journal:  Clin Mol Hepatol       Date:  2016-12-14

6.  Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation.

Authors:  Daniele Nicolini; Andrea Agostini; Roberto Montalti; Federico Mocchegiani; Cinzia Mincarelli; Alessandra Mandolesi; Nicola L Robertson; Roberto Candelari; Andrea Giovagnoni; Marco Vivarelli
Journal:  World J Gastroenterol       Date:  2017-05-28       Impact factor: 5.742

7.  Efficacy of loco-regional treatment for hepatocellular carcinoma prior to living donor liver transplantation: a report from a single center in Egypt.

Authors:  Mohammad Kamal Shaker; Iman F Montasser; Mohamed Sakr; Mohamed Elgharib; Hany M Dabbous; Hend Ebada; Ahmed El Dorry; Mohamed Bahaa; Mahmoud El Meteini
Journal:  J Hepatocell Carcinoma       Date:  2018-02-27

8.  Impact of successful local ablative bridging therapy prior to liver transplantation on long-term survival in patients with hepatocellular carcinoma in cirrhosis.

Authors:  Astrid Bauschke; Annelore Altendorf-Hofmann; Michael Ardelt; Herman Kissler; Hans-Michael Tautenhahn; Utz Settmacher
Journal:  J Cancer Res Clin Oncol       Date:  2020-04-30       Impact factor: 4.553

Review 9.  Combining Chemistry and Engineering for Hepatocellular Carcinoma: Nano-Scale and Smaller Therapies.

Authors:  Danielle L Stolley; Anna Colleen Crouch; Aliçan Özkan; Erin H Seeley; Elizabeth M Whitley; Marissa Nichole Rylander; Erik N K Cressman
Journal:  Pharmaceutics       Date:  2020-12-20       Impact factor: 6.321

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.